Miromatrix to Participate in CareDx’s Xenotransplantation Innovation Day

EDEN PRAIRIE, Minn., March 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced its participation in CareDx’s Xenotransplantation Innovation Day, a virtual event that will feature a leading panel of transplant experts who will share the latest advancements in the field.

CareDx’s Xenotransplantation Innovation Day will be held on March 22, 2022, from 11:00 am to 12:00 pm Central Time / 12:00 pm to 1:00 pm Eastern Time. The presentations and panel discussions will be held in a virtual format to enable a wide audience to learn from these experts.

The symposium will include an update on the world’s first living pig-to-human heart transplant from the University of Maryland School of Medicine, an update on the world’s first transplant of a gene-edited pig kidney from NYU Langone Health, and a development update regarding human-compatible organs from eGenesis and an update on bioengineered livers and kidneys for transplant from Miromatrix.

Registration for the Xenotransplantation Innovation Day is available here.

“We are honored to be invited to speak to the continued advancement and innovation in the transplant field, especially in regard to Miromatrix’s mission to bioengineer transplantable organs,” said Jeff Ross Ph.D, Miromatrix’s CEO. “The national organ transplant waiting list continues to grow, and Miromatrix remains dedicated to serving the transplant community. The innovation day hosted by CareDx brings together transplant experts and partners who all play a pivotal role in improving organ transplants, and Miromatrix looks forward to participating.”

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

About CareDx
CareDx, Inc. (NASDAQ: CDNA), headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward looking statements, including statements regarding our first ever transplant of a bioengineered liver transplant into a large animal. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this press release are only predictions and are based largely on our current business plans, expectations, and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue; our limited history operating as a commercial company; our expectations with respect to the regulatory pathway of our product candidates, our ability to obtain regulatory approvals for such product candidates, and the anticipated effect of delays in obtaining any such regulatory approvals; our expectations with respect to preclinical and clinical trial plans for our product candidates, the results of such activities and the safety and efficacy of our product candidates; our ability to commercialize our product candidates; our ability to compete successfully with larger competitors in our highly competitive industry; our ability to achieve and maintain adequate levels of coverage or reimbursement for any future products we may seek to commercialize; our ability to compete successfully with larger competitors in our highly competitive industry; our expectations regarding our manufacturing capabilities; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus, COVID-19; product liability claims; our ability to establish and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others; our ability to attract and retain senior management and key scientific personnel; and other important factors that could cause actual results, performance or achievements to differ materially from those expected or projected. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Registration Statement on Form S-1 (File No. 333-256649), as amended, filed with the U.S. Securities and Exchange Commission and any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Contact:
Greg Chodaczek
332-895-3230
ir@miromatrix.com

Media Contact:
press@miromatrix.com


Primary Logo

Back to news